Catalogue
Articles
RSS feedX
Search Filters
Format
Subjects
Library Location
Language
Publication Date
1.
Building genetic medicine
: breast cancer, technology, and the comparative politics of health care
2007, 1, Inside technology, ISBN 0262162423, Volume 1, x, 271
A comparative study of genetic testing for breast and ovarian cancer in the United States and Britain that shows the importance of national context in the...
Diagnostic use | Cross-Cultural Comparison | Delivery of Health Care | BRCA genes | Breast | Ovarian Neoplasms | Diagnosis | prevention & control | Breast Neoplasms | Social aspects | Genetic screening | Cancer | Medicine: General Issues | Genetic screaning | United States | Great Britain | General Science | Health Sciences | breast cancer; ovarian cancer; health care; Britain; United States
Diagnostic use | Cross-Cultural Comparison | Delivery of Health Care | BRCA genes | Breast | Ovarian Neoplasms | Diagnosis | prevention & control | Breast Neoplasms | Social aspects | Genetic screening | Cancer | Medicine: General Issues | Genetic screaning | United States | Great Britain | General Science | Health Sciences | breast cancer; ovarian cancer; health care; Britain; United States
Book
Details 
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2009, Volume 106, Issue 17, pp. 7155 - 7160
Mutations in breast cancer susceptibility gene 1 and 2 (BRCA1 and BRCA2) predispose individuals to breast and ovarian cancer development. We previously...
Proteins | BRCA proteins | DNA damage | DNA | Antibodies | Breast cancer | Gene conversion | Genetic mutation | DNA repair | DNA breaks | BRCA2 | FANCN | BRCA1 | PARTNER | PHOSPHORYLATION | DNA-DAMAGE RESPONSE | STABILITY | MULTIDISCIPLINARY SCIENCES | BINDING PROTEIN | FANCONI-ANEMIA | BREAST-CANCER | TARGETS BRCA1 | MUTATION | CANCER SUSCEPTIBILITY GENE | Amino Acid Sequence | Cell Line | Tumor Suppressor Proteins - metabolism | Humans | Nuclear Proteins - metabolism | DNA - metabolism | DNA Repair - genetics | DNA - genetics | BRCA1 Protein - genetics | BRCA2 Protein - metabolism | BRCA1 Protein - metabolism | Tumor Suppressor Proteins - genetics | DNA Breaks | Protein Binding | Nuclear Proteins - genetics | Fanconi Anemia Complementation Group N Protein | BRCA2 Protein - genetics | Genetic aspects | Research | Properties | BRCA mutations | Cancer | Mutation | Genetic recombination | Deoxyribonucleic acid--DNA | Binding sites | Ovarian cancer | BRCA2 protein | scaffolds | BRCA1 protein | homologous recombination | Tumorigenesis | Genomic instability | Index Medicus | Biological Sciences
Proteins | BRCA proteins | DNA damage | DNA | Antibodies | Breast cancer | Gene conversion | Genetic mutation | DNA repair | DNA breaks | BRCA2 | FANCN | BRCA1 | PARTNER | PHOSPHORYLATION | DNA-DAMAGE RESPONSE | STABILITY | MULTIDISCIPLINARY SCIENCES | BINDING PROTEIN | FANCONI-ANEMIA | BREAST-CANCER | TARGETS BRCA1 | MUTATION | CANCER SUSCEPTIBILITY GENE | Amino Acid Sequence | Cell Line | Tumor Suppressor Proteins - metabolism | Humans | Nuclear Proteins - metabolism | DNA - metabolism | DNA Repair - genetics | DNA - genetics | BRCA1 Protein - genetics | BRCA2 Protein - metabolism | BRCA1 Protein - metabolism | Tumor Suppressor Proteins - genetics | DNA Breaks | Protein Binding | Nuclear Proteins - genetics | Fanconi Anemia Complementation Group N Protein | BRCA2 Protein - genetics | Genetic aspects | Research | Properties | BRCA mutations | Cancer | Mutation | Genetic recombination | Deoxyribonucleic acid--DNA | Binding sites | Ovarian cancer | BRCA2 protein | scaffolds | BRCA1 protein | homologous recombination | Tumorigenesis | Genomic instability | Index Medicus | Biological Sciences
Journal Article
Details
Digital rights
Loading RightsPLOS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, p. e0160174
Triple negative breast cancer is typically an aggressive and difficult to treat subtype. It is often associated with loss of function of the BRCA1 gene, either...
BRCA1 protein | Breast cancer | Gene expression | Tissues | Blood | Heterozygosity | Loss of heterozygosity | DNA methylation | Epigenetics | Mutation | Methylation | Health risk assessment | Deoxyribonucleic acid--DNA | Tumors | Cancer | CpG islands | Deoxyribonucleic acid | DNA
BRCA1 protein | Breast cancer | Gene expression | Tissues | Blood | Heterozygosity | Loss of heterozygosity | DNA methylation | Epigenetics | Mutation | Methylation | Health risk assessment | Deoxyribonucleic acid--DNA | Tumors | Cancer | CpG islands | Deoxyribonucleic acid | DNA
Journal Article
Details
Digital rights
Loading Rights
4.
Breast cancer gene research and medical practices
: transnational perspectives in the time of BRCA
2014, Genetics and Society, ISBN 9780415824064, xxii, 225
The discovery of the two inherited susceptibility genes BRCA1 and BRCA2 in the mid-1990s created the possibility of predictive genetic testing and led to the...
BRCA genes | Breast | Genetic aspects | Tumor markers | Cancer | Medicine: General Issues | Health & Medical Anthropology | Anthropology - Soc Sci | New Genetics | Sociology of Science & Technology | Gender Studies | Medicine - Sociology | Bioethics | Genetics - Sociology | Medical Sociology | Sociology & Social Policy | Genetic screening
BRCA genes | Breast | Genetic aspects | Tumor markers | Cancer | Medicine: General Issues | Health & Medical Anthropology | Anthropology - Soc Sci | New Genetics | Sociology of Science & Technology | Gender Studies | Medicine - Sociology | Bioethics | Genetics - Sociology | Medical Sociology | Sociology & Social Policy | Genetic screening
Book
Details
PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 11, pp. e0207399 - e0207399
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the...
HOMOLOGOUS RECOMBINATION REPAIR | PEGYLATED LIPOSOMAL DOXORUBICIN | MULTIDISCIPLINARY SCIENCES | 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP | CERVICAL-CANCER | OPEN-LABEL | ANTITUMOR-ACTIVITY | CELL-LINES | RIBONUCLEOTIDE REDUCTASE-ACTIVITY | ENDOTHELIAL GROWTH-FACTOR | TUMOR-CELL | Humans | Mice, SCID | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Mice, Nude | BRCA1 Protein - metabolism | Cell Line, Tumor | Female | Pyridines - pharmacology | Thiosemicarbazones - pharmacology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Enzyme inhibitors | BRCA mutations | Patient outcomes | Development and progression | Genetic aspects | Drug therapy, Combination | Drug therapy | Health aspects | Methods | Ovarian cancer | Animal models | Severe combined immunodeficiency | Ovarian carcinoma | Xenotransplantation | Homologous recombination | Homology | AKT protein | Kinases | Homologous recombination repair | Ribonucleotide reductase | Xenografts | Protein-tyrosine kinase receptors | Vascular endothelial growth factor | Growth factors | Protein-tyrosine kinase | Tyrosine | Effectiveness | Poly(ADP-ribose) polymerase | Breast cancer | Survival | Inhibitors | Cell lines | Mice | Mutation | Prolongation | Cancer | Tumors | Apoptosis | Reductase | Index Medicus
HOMOLOGOUS RECOMBINATION REPAIR | PEGYLATED LIPOSOMAL DOXORUBICIN | MULTIDISCIPLINARY SCIENCES | 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP | CERVICAL-CANCER | OPEN-LABEL | ANTITUMOR-ACTIVITY | CELL-LINES | RIBONUCLEOTIDE REDUCTASE-ACTIVITY | ENDOTHELIAL GROWTH-FACTOR | TUMOR-CELL | Humans | Mice, SCID | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Mice, Nude | BRCA1 Protein - metabolism | Cell Line, Tumor | Female | Pyridines - pharmacology | Thiosemicarbazones - pharmacology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Enzyme inhibitors | BRCA mutations | Patient outcomes | Development and progression | Genetic aspects | Drug therapy, Combination | Drug therapy | Health aspects | Methods | Ovarian cancer | Animal models | Severe combined immunodeficiency | Ovarian carcinoma | Xenotransplantation | Homologous recombination | Homology | AKT protein | Kinases | Homologous recombination repair | Ribonucleotide reductase | Xenografts | Protein-tyrosine kinase receptors | Vascular endothelial growth factor | Growth factors | Protein-tyrosine kinase | Tyrosine | Effectiveness | Poly(ADP-ribose) polymerase | Breast cancer | Survival | Inhibitors | Cell lines | Mice | Mutation | Prolongation | Cancer | Tumors | Apoptosis | Reductase | Index Medicus
Journal Article
Details
Digital rights
Loading RightsGynecologic Oncology, ISSN 0090-8258, 11/2017, Volume 147, Issue 2, pp. 267 - 275
An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in...
Ovarian carcinoma | Rucaparib | Somatic, germline BRCA mutation | PARP inhibitor | MULTICENTER | SOLID TUMORS | FALLOPIAN-TUBE | OPEN-LABEL | PHASE-2 | OLAPARIB MONOTHERAPY | CARRIERS | OBSTETRICS & GYNECOLOGY | BREAST-CANCER | ONCOLOGY | DNA-REPAIR | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | Neoplasms, Glandular and Epithelial - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Indoles - adverse effects | Neoplasm Grading | Neoplasms, Glandular and Epithelial - drug therapy | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Indoles - therapeutic use | Aged | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Care and treatment | Genetic aspects | Carcinoma | Safety and security measures | Analysis | Cancer | Index Medicus
Ovarian carcinoma | Rucaparib | Somatic, germline BRCA mutation | PARP inhibitor | MULTICENTER | SOLID TUMORS | FALLOPIAN-TUBE | OPEN-LABEL | PHASE-2 | OLAPARIB MONOTHERAPY | CARRIERS | OBSTETRICS & GYNECOLOGY | BREAST-CANCER | ONCOLOGY | DNA-REPAIR | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | Neoplasms, Glandular and Epithelial - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Indoles - adverse effects | Neoplasm Grading | Neoplasms, Glandular and Epithelial - drug therapy | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Indoles - therapeutic use | Aged | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | BRCA2 Protein - genetics | Care and treatment | Genetic aspects | Carcinoma | Safety and security measures | Analysis | Cancer | Index Medicus
Journal Article
Details
Digital rights
Loading Rights2014, ISBN 1613748604, 324
Book
Details
Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 2, pp. 269 - 75
In a cohort of more than 1000 known mutation carriers, BRCA2 mutations are associated with a higher rate of pancreatic cancer than previously reported....
hereditary breast and ovarian cancer syndrome | BRCA | mutation | pancreatic cancer | prostate cancer | genetics | Hereditary breast and ovarian cancer syndrome | Genetics | Prostate cancer | Pancreatic cancer | BRCA mutation | PANCREATIC-CANCER | HUMAN-PAPILLOMAVIRUS | CARRIERS | HIGH-RISK INDIVIDUALS | ONCOLOGY | FAMILIES | SITES | HISTORY | United States - epidemiology | Genetic Predisposition to Disease | Genetic Testing | Pancreatic Neoplasms - epidemiology | Risk Assessment | Humans | Middle Aged | Risk Factors | Male | Pancreatic Neoplasms - genetics | Incidence | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Breast Neoplasms - genetics | Adult | Female | Heterozygote | Aged | Mutation | BRCA2 Protein - genetics | Pancreatic Neoplasms - ethnology | Cohort analysis | Usage | BRCA mutations | Analysis | Genetic aspects | Breast cancer | Diagnosis | Research | Ovarian cancer | Cancer | Index Medicus | Abridged Index Medicus | Hereditary Breast and Ovarian Cancer Syndrome | Prostate Cancer | Pancreatic Cancer | BRCA Mutation
hereditary breast and ovarian cancer syndrome | BRCA | mutation | pancreatic cancer | prostate cancer | genetics | Hereditary breast and ovarian cancer syndrome | Genetics | Prostate cancer | Pancreatic cancer | BRCA mutation | PANCREATIC-CANCER | HUMAN-PAPILLOMAVIRUS | CARRIERS | HIGH-RISK INDIVIDUALS | ONCOLOGY | FAMILIES | SITES | HISTORY | United States - epidemiology | Genetic Predisposition to Disease | Genetic Testing | Pancreatic Neoplasms - epidemiology | Risk Assessment | Humans | Middle Aged | Risk Factors | Male | Pancreatic Neoplasms - genetics | Incidence | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Breast Neoplasms - genetics | Adult | Female | Heterozygote | Aged | Mutation | BRCA2 Protein - genetics | Pancreatic Neoplasms - ethnology | Cohort analysis | Usage | BRCA mutations | Analysis | Genetic aspects | Breast cancer | Diagnosis | Research | Ovarian cancer | Cancer | Index Medicus | Abridged Index Medicus | Hereditary Breast and Ovarian Cancer Syndrome | Prostate Cancer | Pancreatic Cancer | BRCA Mutation
Journal Article
Details
Digital rights
Loading RightsNature Structural & Molecular Biology, ISSN 1545-9993, 06/2010, Volume 17, Issue 6, pp. 688 - 695
Germ-line mutations in breast cancer 1, early onset (BRCA1) result in predisposition to breast and ovarian cancer. BRCA1-mutated tumors show genomic...
STEM-CELLS | GENE BRCA1 | DNA-DAMAGE RESPONSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CONDITIONAL MOUSE MODEL | DOUBLE-STRAND BREAKS | OVARIAN-CANCER | CELL BIOLOGY | GENOMIC INSTABILITY | MAMMARY-TUMORS | BIOPHYSICS | TUMOR-SUPPRESSOR | CELL-CYCLE | Embryonic Stem Cells - metabolism | Cell Proliferation | Embryonic Stem Cells - cytology | Humans | Breast Neoplasms - metabolism | Intracellular Signaling Peptides and Proteins - deficiency | Gene Deletion | Genes, BRCA2 | Female | Genes, BRCA1 | Tumor Cells, Cultured | BRCA1 Protein - deficiency | Intracellular Signaling Peptides and Proteins - genetics | DNA-Binding Proteins | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Chromosomal Proteins, Non-Histone | Breast Neoplasms - drug therapy | Mice, Knockout | BRCA1 Protein - genetics | Drug Resistance, Neoplasm - genetics | Animals | Apoptosis Regulatory Proteins | Breast Neoplasms - genetics | Cell Cycle | Breast Neoplasms - pathology | DNA Repair | BRCA2 Protein - deficiency | Mice | Mutagenesis, Insertional | DNA Damage | Mutation | Tumor Suppressor p53-Binding Protein 1 | Drug Resistance, Neoplasm - physiology | BRCA2 Protein - genetics | BRCA mutations | DNA damage | Physiological aspects | Breast cancer | Genetic aspects | Research | Health aspects | DNA repair | Risk factors | Molecular biology | Ovarian cancer | Index Medicus
STEM-CELLS | GENE BRCA1 | DNA-DAMAGE RESPONSE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CONDITIONAL MOUSE MODEL | DOUBLE-STRAND BREAKS | OVARIAN-CANCER | CELL BIOLOGY | GENOMIC INSTABILITY | MAMMARY-TUMORS | BIOPHYSICS | TUMOR-SUPPRESSOR | CELL-CYCLE | Embryonic Stem Cells - metabolism | Cell Proliferation | Embryonic Stem Cells - cytology | Humans | Breast Neoplasms - metabolism | Intracellular Signaling Peptides and Proteins - deficiency | Gene Deletion | Genes, BRCA2 | Female | Genes, BRCA1 | Tumor Cells, Cultured | BRCA1 Protein - deficiency | Intracellular Signaling Peptides and Proteins - genetics | DNA-Binding Proteins | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Chromosomal Proteins, Non-Histone | Breast Neoplasms - drug therapy | Mice, Knockout | BRCA1 Protein - genetics | Drug Resistance, Neoplasm - genetics | Animals | Apoptosis Regulatory Proteins | Breast Neoplasms - genetics | Cell Cycle | Breast Neoplasms - pathology | DNA Repair | BRCA2 Protein - deficiency | Mice | Mutagenesis, Insertional | DNA Damage | Mutation | Tumor Suppressor p53-Binding Protein 1 | Drug Resistance, Neoplasm - physiology | BRCA2 Protein - genetics | BRCA mutations | DNA damage | Physiological aspects | Breast cancer | Genetic aspects | Research | Health aspects | DNA repair | Risk factors | Molecular biology | Ovarian cancer | Index Medicus
Journal Article
Details
Digital rights
Loading RightsJournal of Medical Genetics, ISSN 0022-2593, 04/2006, Volume 43, Issue 4, pp. 295 - 305
Background: Genetic testing for hereditary cancer syndromes contributes to the medical management of patients who may be at increased risk of one or more...
SEQUENCE-ANALYSIS | UNKNOWN CLINICAL-SIGNIFICANCE | VARIANTS | GENE BRCA1 | MOUSE | GENETICS & HEREDITY | CANCER SUSCEPTIBILITY | EMBRYONIC LETHALITY | MUTATIONS | FAMILY-HISTORY | BREAST | Haplotypes | Amino Acid Sequence | Data Interpretation, Statistical | Ovarian Neoplasms - diagnosis | Humans | Mutation, Missense | DNA Mutational Analysis - methods | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Sequence Alignment | Breast Neoplasms - genetics | Genes, BRCA2 | Female | Breast Neoplasms - diagnosis | Genes, BRCA1 | BRCA1 Protein - chemistry | Amino Acid Substitution | Evolution, Molecular | Genetic susceptibility | BRCA mutations | Breast cancer | Research | Identification and classification | Risk factors | Genetic polymorphisms | Oncogenes | Studies | Genes | Classification | Genetics | Genomes | Mutation | Family medical history | Genetic testing | Patients | Deoxyribonucleic acid--DNA | Methods | Cancer | Index Medicus | missense substitution | A‐GVGD | co‐occurrence | Grantham difference | polymorphism | BRCA1 | Original
SEQUENCE-ANALYSIS | UNKNOWN CLINICAL-SIGNIFICANCE | VARIANTS | GENE BRCA1 | MOUSE | GENETICS & HEREDITY | CANCER SUSCEPTIBILITY | EMBRYONIC LETHALITY | MUTATIONS | FAMILY-HISTORY | BREAST | Haplotypes | Amino Acid Sequence | Data Interpretation, Statistical | Ovarian Neoplasms - diagnosis | Humans | Mutation, Missense | DNA Mutational Analysis - methods | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Sequence Alignment | Breast Neoplasms - genetics | Genes, BRCA2 | Female | Breast Neoplasms - diagnosis | Genes, BRCA1 | BRCA1 Protein - chemistry | Amino Acid Substitution | Evolution, Molecular | Genetic susceptibility | BRCA mutations | Breast cancer | Research | Identification and classification | Risk factors | Genetic polymorphisms | Oncogenes | Studies | Genes | Classification | Genetics | Genomes | Mutation | Family medical history | Genetic testing | Patients | Deoxyribonucleic acid--DNA | Methods | Cancer | Index Medicus | missense substitution | A‐GVGD | co‐occurrence | Grantham difference | polymorphism | BRCA1 | Original
Journal Article
Details
Digital rights
Loading Rights2009, ISBN 9780156033312, 321
Book
Details
11/2012
A bilateral salpingo oophorectomy (BSO), removal of the ovaries, is recommended for carriers of BRCA1/2 mutations to reduce cancer risks. However, BSO induces...
brca | 0633 | estrogen | cognition | oophorectomy
brca | 0633 | estrogen | cognition | oophorectomy
Dissertation
Details
Journal of Biological Chemistry, ISSN 0021-9258, 04/2011, Volume 286, Issue 15, pp. 13669 - 13680
The tumor suppressor protein BRCA1 is a constituent of several different protein complexes and is required for homology-directed repair (HDR) of DNA double...
CHECKPOINT CONTROL | DAMAGE RESPONSE | TARGETS BRCA1 | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANCER SUSCEPTIBILITY | DOUBLE-STRAND BREAKS | CELL-CYCLE | HOMOLOGOUS RECOMBINATION | FANCONI-ANEMIA | MAMMALIAN-CELLS | Chromatin - metabolism | G2 Phase - physiology | Membrane Proteins - genetics | Humans | DNA Repair - physiology | Genomic Instability - physiology | Nuclear Proteins - metabolism | DNA-Binding Proteins - genetics | DNA Breaks, Double-Stranded | Multiprotein Complexes - physiology | DNA-Binding Proteins - metabolism | BRCA1 Protein - genetics | Carrier Proteins - genetics | MRE11 Homologue Protein | Carrier Proteins - metabolism | BRCA1 Protein - metabolism | S Phase - physiology | Membrane Proteins - metabolism | HeLa Cells | Nuclear Proteins - genetics | Chromatin - genetics | Index Medicus | Ubiquitin | BRCC36 | DNA and Chromosomes | BRCA BRCB | Deubiquitination | DNA Repair | BRCA1 | RAP80 | DNA Recombination
CHECKPOINT CONTROL | DAMAGE RESPONSE | TARGETS BRCA1 | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANCER SUSCEPTIBILITY | DOUBLE-STRAND BREAKS | CELL-CYCLE | HOMOLOGOUS RECOMBINATION | FANCONI-ANEMIA | MAMMALIAN-CELLS | Chromatin - metabolism | G2 Phase - physiology | Membrane Proteins - genetics | Humans | DNA Repair - physiology | Genomic Instability - physiology | Nuclear Proteins - metabolism | DNA-Binding Proteins - genetics | DNA Breaks, Double-Stranded | Multiprotein Complexes - physiology | DNA-Binding Proteins - metabolism | BRCA1 Protein - genetics | Carrier Proteins - genetics | MRE11 Homologue Protein | Carrier Proteins - metabolism | BRCA1 Protein - metabolism | S Phase - physiology | Membrane Proteins - metabolism | HeLa Cells | Nuclear Proteins - genetics | Chromatin - genetics | Index Medicus | Ubiquitin | BRCC36 | DNA and Chromosomes | BRCA BRCB | Deubiquitination | DNA Repair | BRCA1 | RAP80 | DNA Recombination
Journal Article
Details
Digital rights
Loading RightsFamilial Cancer, ISSN 1389-9600, 1/2019, Volume 18, Issue 1, pp. 29 - 35
Despite some populations show a wide spectrum of different BRCA pathogenic variants (PVs), particular ethnic groups carry at high frequency a single or a few...
Human Genetics | Biomedicine, general | Biomedicine | Italian founder BRCA1 / 2 mutations | Capillary electrophoresis | Cancer Research | BRCA1 / 2 genes | Epidemiology | BRCA1/2 genes | Italian founder BRCA1/2 mutations | NORTHEAST | GERMLINE | RECURRENT MUTATIONS | BRCA1 | OVARIAN-CANCER | IDENTIFICATION | 2 mutations | BREAST | BRCA2 GENES | ONCOLOGY | FAMILIES | GENETICS & HEREDITY | Italian founder BRCA1 | 2 genes | Genotyping | BRCA1 protein | Risk assessment | Breast cancer | Founder effect | Minority & ethnic groups | Cancer | Index Medicus
Human Genetics | Biomedicine, general | Biomedicine | Italian founder BRCA1 / 2 mutations | Capillary electrophoresis | Cancer Research | BRCA1 / 2 genes | Epidemiology | BRCA1/2 genes | Italian founder BRCA1/2 mutations | NORTHEAST | GERMLINE | RECURRENT MUTATIONS | BRCA1 | OVARIAN-CANCER | IDENTIFICATION | 2 mutations | BREAST | BRCA2 GENES | ONCOLOGY | FAMILIES | GENETICS & HEREDITY | Italian founder BRCA1 | 2 genes | Genotyping | BRCA1 protein | Risk assessment | Breast cancer | Founder effect | Minority & ethnic groups | Cancer | Index Medicus
Journal Article
Details
Digital rights
Loading Rights
15.
Pieces of me
2009, Health and society in video
Pieces of me puts a human face to the accelerating scientific advancements in genetic identification. The science of genetics is expanding faster than cures or...
BRCA genes | Cancer
BRCA genes | Cancer
Web Resource
Details